# Disiontech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/disiontech

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.disiontech.com
- Latest round: Series A (Mar 5, 2025)
- Investors on record: 2

## About

Established in 2019 and based in Shenzhen, China, Disiontech operates as a medical equipment developer that mainly provides intelligent visual meibomian gland treatment device. In March 2025, the company closed series A funding from new investors Triwise Capital and OVC TEK.

The company specializes in the research, development, production, and sales of advanced ophthalmic medical devices. Its core product, the DisionEyemore intelligent visualized meibomian gland treatment device, addresses meibomian gland dysfunction, a common cause of dry eye disease. Disiontech primarily serves hospitals and clinics in China, collaborating with ophthalmology institutions.

The company generates revenue through direct sales of its ophthalmic products to healthcare facilities and professionals, emphasizing B2B transactions. The company’s flagship device, the DisionEyemore, is central to its offerings, with transactions typically involving bulk purchases. 

The company will use the venture funding for clinical trials of the intelligent corneal cross-linking device and the sales and promotion of the meibomian gland therapeutic device. It intends to launch updated versions of its DisionEyemore device in 2025, targeting hospitals throughout Southeast Asia and Europe by 2026.

## Funding rounds

- Series A, Mar 5, 2025 — OVC TEK, Triwise Capital

## Investors

- OVC TEK — Series A
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A